[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636156":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":11,"locations":34,"responsibleParty":48,"collaborators":11,"id":50,"slug":11,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":11,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":11,"overallStatus":68,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Sinocelltech Ltd.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"SCTB35 and Lenalidomide","EXPERIMENTAL",null,[13,14],"Drug: SCTB35 injection","Drug: Lenalidomide",{"label":16,"type":17,"description":11,"interventionNames":18},"Rituximab and Lenalidomide","ACTIVE_COMPARATOR",[19,14],"Drug: Rituximab",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"DRUG","SCTB35 injection","SCTB35 will be subcutaneously administered at a dose as specified",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Rituximab","Intravenous Infusion",[16],{"type":22,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"Lenalidomide","Oral Capsules",[16,9],[35],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":11},"Beijing Cancer Hospital","Beijing","Beijing Municipality","100142","China","CN",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100636156",false,"NCT07562022","A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide Versus Rituximab and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","Inclusion Criteria:\n\n* Age 18-80 years old\n* Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria\n* Relapsed or refractory (R\u002FR) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy\n* Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion\n* A measurable or evaluable disease at the time of enrolment\n* ECOG PS 0-2\n* Adequate organ function and bone marrow function\n* Expected survival ≥ 6 months\n\nExclusion Criteria:\n\n* Documented refractoriness to lenalidomide.\n* Have lenalidomide exposure within 12 months prior to randomization","ALL","18 Years","80 Years",{"count":60,"type":61},93,"ESTIMATED","INTERVENTIONAL",[64],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).",[67],"Follicular Lymphoma (FL)","NOT_YET_RECRUITING","2026-04-24",{"date":71,"type":72},"2026-05-01","ACTUAL",{"date":74,"type":61},"2026-05",{"date":76,"type":61},"2029-06",{"name":5,"class":6},1]